Bone-targeted polymer therapeutics for non-union fracture healing

用于骨不连骨折愈合的骨靶向聚合物治疗

基本信息

  • 批准号:
    10681217
  • 负责人:
  • 金额:
    $ 22.13万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-08-15 至 2025-04-30
  • 项目状态:
    未结题

项目摘要

Of the more than 15 million Americans suffer from fractures each year, 5% result in nonunions. Standard nonunion management is revision surgery: debridement, followed by autograft, and/or additional fixation. However, revision surgery carries risks inherent to any surgery and fails in up to 60% of cases due to underlying comorbidities. Therefore, novel therapeutics for treating nonunions are critical and should obviate surgery through noninvasive delivery or increase revision surgery success. There is a reduction in overall number and regenerative capacity of MSCs within a critical sized defect. Deficient MSCs reduces cartilage and bone formation, soft callus remodeling, mineralization, and expression of critical osteogenic growth factors within the callus. Additionally, prolonged inflammation contributes to aging-related changes that underlie nonunion development. Despite the promise of several drug candidates for augmenting MSC function for nonunion healing, side effects due to poor fracture biodistribution have hampered development. Thus, a critical technological gap exists in delivery of potent, regenerative drugs to fracture sites while limiting biodistribution to off-target tissues to improve safety and clinical translatability. To address these hurdles, we have developed a fracture-targeted nanoparticle (NP)-based delivery system for the GSK-3β inhibitor AR28 to upregulate the regenerative Wnt/β-catenin pathway. Targeting is achieved by incorporation of a peptide that binds specifically to tartrate resistant acid phosphatase (TRAP5b), a matrix-bound protein deposited by osteoclasts throughout healing and at nonunions. TRAP5b-binding peptide (TBP) targeted NP exhibit preferential accumulation at conventional femur fractures. Fracture localized activation of β-catenin is greatly increased compared with untreated, free drug, untargeted NP, and scrambled peptide NP controls. Expedited callus formation was observed in fractures treated with TBP-NPAR28 versus controls with more rapid callus ossification. Finally, the maximum torque to failure of treated fractures was ~3-4-fold greater than controls 4 weeks after treatments. However, the potential of this technology within more clinically relevant situations (e.g., acute and established fracture nonunions in adult and aged models) is critical for further development, setting up this high-risk/high-reward proposal. With the hypothesis that TBP-NPAR28 will enable drug delivery to promote healing in fracture nonunions in aged and adult mice, the following aims are proposed: Aim 1: Assess the therapeutic effect of a TBP-NPAR28 for the prevention of nonunion in adult and aged murine models. Aim 2: Assess the therapeutic effect of TBP-NPAR28 in fully established nonunions in adult and aged mice. Successful completion of these Aims will significantly advance our ability to target drugs to prevent or enable healing of adult and aged nonunion fractures.
在每年超过1500万的美国人中,有5%的人会导致骨不连。标准 骨不连的处理是翻修手术:清创,然后是自体移植,和/或附加固定。 然而,翻修手术带有任何手术固有的风险,在高达60%的病例中失败是因为 潜在的合并症。因此,治疗骨不连的新疗法是至关重要的,应该被排除。 通过无创分娩进行手术或增加翻修手术的成功率。总体上是减少了 临界大小缺损区内间充质干细胞的数量和再生能力。骨髓间充质干细胞缺乏会减少软骨和 骨形成、软骨痂改建、矿化和关键成骨生长因子的表达 在老茧里。此外,长期的炎症也会导致与衰老相关的变化。 非工会发展。尽管几种候选药物承诺增强MSC的功能 骨折生物分布不良导致的骨不连愈合和副作用阻碍了骨折的发展。因此,一个 在将有效的、可再生的药物输送到骨折部位方面存在关键技术差距,同时限制了 生物分布到靶外组织,以提高安全性和临床可译性。为了解决这些障碍,我们 已经为葛兰素史克-3β抑制剂ar28开发了一种基于骨折靶向纳米颗粒(NP)的递送系统 上调再生的Wnt/β-连环蛋白途径。靶向是通过掺入一种多肽来实现的 与抗酒石酸酸性磷酸酶(TRAP5b)特异性结合,TRAP5b是一种与基质结合的蛋白质,由 在愈合和骨不连过程中的破骨细胞。TRAP5b结合肽(TBP)靶向NP展示 在常规股骨骨折处优先堆积。β-连环蛋白在骨折局部的激活作用显著 与未经治疗的、游离药物、非靶向NP和杂乱的多肽NP对照相比增加。已加快 在TBP-NPAR28治疗的骨折组与骨痂更快的对照组相比,观察到了骨痂的形成 骨化。最后,接受治疗的骨折的最大失效扭矩是对照组的3-4倍。 治疗后几周。然而,该技术在更临床相关的情况下的潜力(例如, 成人和老年模型中急性和已建立的骨折不愈合)对进一步发展、设置 提高这个高风险/高回报的提议。假设TBP-NPAR28将使药物输送到 为了促进老年和成年小鼠骨折不愈合的愈合,提出了以下目标: 目的1:评价TBP-NPAR28预防成人和老年人骨不连的疗效 小鼠模型。 目的2:评价TBP-NPAR28治疗成人和老年人完全骨不连的疗效 老鼠。 成功完成这些目标将大大提高我们针对药物进行预防或使 成人和老年骨不连骨折的愈合。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Danielle S. Benoit其他文献

Danielle S. Benoit的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Danielle S. Benoit', 18)}}的其他基金

Tissue Engineering Strategies to Revitalize Allografts
振兴同种异体移植物的组织工程策略
  • 批准号:
    10830613
  • 财政年份:
    2023
  • 资助金额:
    $ 22.13万
  • 项目类别:
Using hiPSCs to develop physiologically-relevant outer retina tissue mimetics
使用 hiPSC 开发生理相关的外视网膜组织模拟物
  • 批准号:
    10467753
  • 财政年份:
    2022
  • 资助金额:
    $ 22.13万
  • 项目类别:
Tendon TRAP: Targeted Therapeutic Delivery to Enhance Tendon Healing
Tendon TRAP:有针对性的治疗交付以增强肌腱愈合
  • 批准号:
    10461486
  • 财政年份:
    2022
  • 资助金额:
    $ 22.13万
  • 项目类别:
Tendon TRAP: Targeted Therapeutic Delivery to Enhance Tendon Healing
Tendon TRAP:有针对性的治疗交付以增强肌腱愈合
  • 批准号:
    10612076
  • 财政年份:
    2022
  • 资助金额:
    $ 22.13万
  • 项目类别:
Bone-targeted polymer therapeutics for nonunion fracture healing
用于骨不连骨折愈合的骨靶向聚合物治疗
  • 批准号:
    10371267
  • 财政年份:
    2022
  • 资助金额:
    $ 22.13万
  • 项目类别:
Bone-targeted polymer therapeutics for non-union fracture healing
用于骨不连骨折愈合的骨靶向聚合物治疗
  • 批准号:
    10733942
  • 财政年份:
    2022
  • 资助金额:
    $ 22.13万
  • 项目类别:
Using hiPSCs to develop physiologically-relevant outer retina tissue mimetics
使用 hiPSC 开发生理相关的外视网膜组织模拟物
  • 批准号:
    10709483
  • 财政年份:
    2022
  • 资助金额:
    $ 22.13万
  • 项目类别:
hiPSC-derived tissue mimetics of the retina blood barrier
hiPSC 衍生的视网膜血屏障组织模拟物
  • 批准号:
    10080730
  • 财政年份:
    2020
  • 资助金额:
    $ 22.13万
  • 项目类别:
Engineered salivary gland tissue chips
工程唾液腺组织芯片
  • 批准号:
    10224168
  • 财政年份:
    2017
  • 资助金额:
    $ 22.13万
  • 项目类别:
Engineered salivary gland tissue chips (Administrative Supplement)
工程唾液腺组织芯片(行政补充)
  • 批准号:
    10426429
  • 财政年份:
    2017
  • 资助金额:
    $ 22.13万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 22.13万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 22.13万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 22.13万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 22.13万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 22.13万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 22.13万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 22.13万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 22.13万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 22.13万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 22.13万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了